SCHEMBL8513693

SCHEMBL8513693

Cc1cc(=O)oc2cc(NC(=O)O)ccc12

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.81
CA9 Q16790 5/20 0.81
CA1 P00915 3/20 0.81
ALDH1A1 P00352 6/20 0.73
KDM4E B2RXH2 5/20 0.73
HPGD P15428 4/20 0.73
GAA P10253 2/20 0.73
GLA P06280 1/20 0.73
RAB9A P51151 5/20 0.71
NPC1 O15118 5/20 0.71
HSD17B10 Q99714 2/20 0.71
SMN1; SMN2 Q16637 2/20 0.71
MEN1 O00255 1/20 0.70
KMT2A Q03164 1/20 0.70
LMNA P02545 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
TDP1 Q9NUW8 2/20 0.64
CTDSP1 Q9GZU7 1/20 0.63
MAPT P10636 1/20 0.63
NPSR1 Q6W5P4 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11232995 0.90 CA12 (0.74) CA12CA9CA1ALDH1A1KDM4E
SCHEMBL30449676 0.89 CA12 (1.00) CA12CA9CA1ALDH1A1KDM4E
SCHEMBL8516165 0.89 CA12 (1.00) CA12CA9CA1ALDH1A1KDM4E
SCHEMBL22685138 0.88 CA12 (0.76) CA12CA9CA1ALDH1A1KDM4E
SCHEMBL15747020 0.88 CA12 (0.76) CA12CA9CA1ALDH1A1KDM4E
SCHEMBL26499773 0.88 CA12 (0.62) CA12CA9CA1ALDH1A1KDM4E
SCHEMBL119578 0.87 RAB9A (0.78) CA12CA9CA1ALDH1A1KDM4E
SCHEMBL12417224 0.86 NPC1 (0.76) CA12CA9CA1ALDH1A1KDM4E
SCHEMBL11227792 0.85 CA12 (0.72) CA12CA9CA1ALDH1A1KDM4E
SCHEMBL11231059 0.85 KDM4E (0.74) CA12CA9CA1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2771488-B1 CARBONIC ANHYDRASE IX-RELATED MARKERS AND USE THEREOF SIGNALCHEM LIFESCIENCES CORP (CA) 2018-03-28 EP claimed
US-20140148400-A1 CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY METASIGNAL THERAPEUTICS INC. (CA) 2014-05-29 US claimed
EP-2857018-B1 Treatment or prophylaxis of proliferative conditions UNIV COURT OF THE UNIV OF DUNDEE (GB) 2025-09-03 EP disclosed
US-11993625-B2 Calicheamicin derivatives and antibody drug conjugates thereof PFIZER, INC. (US) 2024-05-28 US disclosed
US-20190345186-A1 CALICHEAMICIN DERATIVES AND ANTIBODY DRUG CONJUGATES THEREOF PFIZER INC. (US) 2019-11-14 US disclosed
WO-2018138591-A1 CALICHEAMICIN DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF PFIZER INC. (US) 2018-08-02 WO disclosed
US-20140148400-A1 CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY METASIGNAL THERAPEUTICS INC. (CA) 2014-05-29 US disclosed
US-8283340-B2 Treatment or prophylaxis of proliferative conditions The University of the University of Dundee (GB) 2012-10-09 US disclosed
WO-2012070024-A1 CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY METASIGNAL THERAPEUTICS INC. (CA) 2012-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148400-A1 CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY CA7, CA4, CA2 CA12 10/4885CA9 4/4885CA1 5/4885
US-20190345186-A1 CALICHEAMICIN DERATIVES AND ANTIBODY DRUG CONJUGATES THEREOF CALD1, CALU, STT3A CA12 36/4885CA9 117/4885CA1 691/4885
US-11993625-B2 Calicheamicin derivatives and antibody drug conjugates thereof STT3A, CLSPN, STT3B CA12 120/4885CA9 194/4885CA1 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.